$2.205
-0.005 (-0.23%)At close
HIND News
HIND Events
Vyome Holdings Appoints Jerry Leonard as CFO
In a regulatory filing, the company stated, "On August 27, 2026, the board of directors of Vyome Holdings appointed Jerry Leonard as the company's Chief Financial Officer. In connection with Leonard's appointment, the Board, upon the recommendation of the compensation committee of the Board, approved a Consulting Agreement with ClearbridgeCFO, LLC, a Georgia limited liability company, and Leonard, pursuant to which ClearBridge will assign Leonard to provide services as the company's Chief Financial Officer, effective as of September 1, 2026. In connection with his appointment, as of the Effective Date, Leonard will serve as the company's principal financial officer and principal accounting officer. On August 25, 2026, Robert Dickey notified the company's board of directors of his intention to voluntary resignation from his position as Interim Chief Financial Officer effective August 31, 2026. Dickey's resignation was not the result of any disagreement with the company on any matter relating to the company's operations, policies, or practices. In connection with Dickey's resignation, the company's consulting agreement with Foresite Advisors, LLC, dated August 26, 2024, will be deemed terminated as of August 31, 2026."
Vyome Holdings Cash and Cash Equivalents Reach $7.9 Million
Cash and cash equivalents were approximately $7.9 million as of June 30, 2026, compared with approximately $5.0 million as of December 31, 2025. Krishna Gupta, Chairman, Vyome Holdings, said, "Vyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capital allocation. During the quarter, we advanced our lead VT-1953 program, broadened our pipeline through the Impetis agreement and continued to strengthen our intellectual property portfolio. With a strong balance sheet and disciplined capital structure, we believe Vyome is well positioned to pursue its development priorities and create long-term shareholder value."
Vyome Holdings Signs Exclusive Agreement with Impetis Biosciences
Vyome Holdings announced the signing of an agreement with Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. "We are building Vyome with focus and discipline in one of the most attractive segments in biotech, the immuno-inflammatory market, expected to exceed $430 billion by 2034, with the JAK inhibitor segment alone representing a significant ~$57 billion opportunity," said Venkat Nelabhotla, CEO of Vyome. "This transaction highlights the strength of the US-India innovation corridor in sourcing high-quality assets efficiently. The transaction is structured to be very capital-efficient, with consideration tied to commercialization. Any future development will be driven through non-dilutive pathways, allowing us to remain fully focused on executing our core strategy around VT-1953."
Vyome Holdings Presents VT-1953 Study Results
Vyome Holdings presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds, MFW, at the 2026 American Association for Cancer Research, AACR, Annual Meeting in San Diego, on April 21, 2026. Key highlights: VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control; 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14; Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 as scored using a 10-point VAS scale. No change seen in vehicle-treated arm.
Vyome to Present VT-1953 Study Data at AACR Annual Meeting
Vyome Holdings will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds at the 2026 American Association for Cancer Research Annual Meeting, taking place on April 17-22, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved drugs to treat malodor and other symptoms of MFW. We plan to have FDA interactions in Q2 2026 on the pivotal study design. Recent third-party analysts estimated the total addressable U.S. market to be approximately $2.2B. Inflammation is one of the biggest healthcare problems facing the world today." The research will be presented at the session "Phase II and Phase III Clinical Trials in Progress." Vyome will highlight mechanistic insights together with detailed clinical data comparing the VT-1953 active treatment with vehicle treatment in a Phase 2 study. VT-1953 is a first-in-class treatment for malodor and other symptoms of MFW in advanced cancer patients, which acts by a dual mechanism of action, inhibiting DNA Gyr and modulating MD2/TLR interactions, an inflammatory signal. MFW is a rare, debilitating condition that occurs in ~10% of advanced cancer patients, severely impacting the quality of life.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.